+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07636785

Evaluating Safety, Tolerability, and Preliminary Effectiveness of Oral VMD-102 in Adults with Advanced Liver Cancer and Other Solid Tumors

Led by VM Discovery, Inc. · Updated on 2026-11-03

111

Participants Needed

2

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and preliminary anti-tumor effectiveness of VMD-102, an oral tablet drug that selectively inhibits PKC epsilon kinase, in adults with advanced liver cancer HCC and other solid tumors including metastatic uveal melanoma, renal cell carcinoma, non-small cell lung cancer, and colorectal cancer. This study has two phases Phase 1 focuses on finding the recommended dose and assessing safety, while Phase 2 looks at early signs of anti-tumor activity. Biomarkers and drug behavior in the body will also be studied. In Phase 1, approximately 25 participants will receive escalating doses of VMD-102 over 21-day cycles to determine the maximum tolerated dose and recommended Phase 2 dose, with safety and drug levels monitored. Phase 2 will enroll about 86 participants divided into two cohorts one with HCC and another with the other cancers combined, to assess anti-tumor effects and safety at the recommended dose. Biomarker-guided enrollment may be added later. Both phases include tissue and blood sample collection for biomarker studies. Participants will undergo regular evaluations including safety assessments, blood tests for drug levels, and imaging scans to measure tumor response up to 18 months. Researchers will monitor treatment-emergent side effects, progression-free survival, and other clinical outcomes. The study includes close monitoring for dose-limiting toxicities during the first treatment cycle and continues safety and efficacy assessments throughout treatment and follow-up periods lasting up to 18 months.

CONDITIONS

Brief Title

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

Research Team

J

Jay Wu, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here